As of February 4, 2019, 51 serious and 14 non-serious cases of immune-related myositis have been reported in patients receiving TECENTRIQ treatment including, 4 with a fatal outcome. There were no Canadian cases reported.
Products affected
TECENTRIQ (atezolizumab) concentrate for solution for infusion, 60 mg / mL in 20 mL single use vials.
Background information
TECENTRIQ has received market authorization in Canada for use in the following clinical settings:
1.
Locally Advanced or Metastatic Urothelial Carcinoma
TECENTRIQ has been issued marketing authorization with conditions, meaning that conditions apply, pending the results of studies to verify its clinical benefit for the treatment of patients with
locally advanced or metastatic urothelial carcinoma who:
-
have disease progression during or following platinum-containing chemotherapy; or
-
have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy.
2.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
TECENTRIQ has been issued marketing authorization for the treatment of adult patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving TECENTRIQ.
Myositis or inflammatory myopathies are a group of disorders sharing the common feature of inflammatory muscle injury. Dermatomyositis and polymyositis are among the most common disorders. Diagnosis is based on clinical (muscle weakness, muscle pain, skin rash in dermatomyositis), biochemical (serum creatine-kinase increase), and imaging (electromyography/MRI) features, and is confirmed with a muscle-biopsy.
As of February 4, 2019, a comprehensive analysis was performed across the TECENTRIQ program and identified 51 serious and 14 non-serious cases of immune-related myositis. Of the identified serious and non-serious cases, 53 were from clinical trials and 12 from post-marketing. Of the 53 clinical trial cases, 5 were identified as category A confirmed with a muscle biopsy. There were no Canadian cases reported. Approximately 19,323 clinical trial patients and 28,975 post-marketing patients have been exposed to TECENTRIQ as of Nov 17, 2018. The incidence of myositis (including related terms of dermatomyositis, polymyositis, rhabdomyolysis) observed across the atezolizumab monotherapy clinical program was <0.1%. Based on the assessment of all available data, immune-related myositis is considered an important identified risk for TECENTRIQ.